Skip to main content

Table 2 Baseline COIVD-19 symptoms

From: Safety and efficacy of hydroxychloroquine for treatment of non-severe COVID-19 among adults in Uganda: a randomized open label phase II clinical trial

Characteristics Arm 1:
HCQ + SOC
Arm 2:
SOC alone
Total
Number randomized 55 50 105
Number with baseline symptom informationa 55 49 104
General symptoms, n (%)    
Fever 5 (9.1) 4 (8.2) 9 (8.7)
Tiredness 5 (9.1) 3 (6.1) 8 (7.7)
Muscle aches 4 (7.3) 5 (10.2) 9 (8.7)
Cardio-respiratory, n (%)    
Coughb 24 (43.6) 21 (42.9) 45 (43.3)
Running nose 11 (20.0) 4 (8.2) 15 (14.4)
Nasal congestion 5 (9.1) 3 (6.1) 8 (7.7)
Sore throat 3 (5.5) 2 (4.1) 5 (4.8)
Difficulty in breathing 1 (1.8) 0 1 (0.9)
Fast breathing 0 0 0
Chest pain 7 (12.7) 5 (10.2) 12 (11.5)
Neurological, n (%)    
Headache 14 (25.5) 11 (22.4) 25 (24.0)
Dizziness 1 (1.8) 3 (6.1) 4 (3.8)
Loss of smell 7 (12.7) 5 (10.2) 12 (11.5)
Loss of taste 5 (9.1) 4 (8.2) 9 (8.7)
Gastrointestinal, n (%)    
Poor appetite 5 (9.1) 4 (8.2) 9 (8.7)
  1. a1 participant (in SOC alone) had missing baseline symptom information. Percentages computed on complete cases
  2. b73% (63% in HCQ group, 86% in SOC group) had dry cough among those reported cough